Does the likelihood of having a BRCA gene mutation differ among populations? Who should consider genetic counseling and testing for inherited harmful changes in BRCA1 and BRCA2 ? How is genetic testing for harmful changes in BRCA1 and BRCA2 done?

Evidence-based, expert-reviewed summary about the BRCA1 and BRCA2 genes and hereditary breast and ovarian cancer. This summary also contains information about the cancer risks associated with BRCA1/BRCA2, screening, risk-reduction, treatment, and prognosis.

Hoja informativa sobre los genes BRCA1 y BRCA2, qué hacer si la prueba de una persona indica que tiene cambios en uno de estos genes y las consecuencias de las pruebas genéticas.

Apr 15, 2024 · Those with harmful BRCA1 or BRCA2 changes who had the surgery, the study found, had a lower risk of dying from ovarian cancer and breast cancer than those who didn’t. Results from both studies were published February 29 in JAMA Oncology.

NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer. From this research, a screening test was also developed to help patients make informed decisions about their health.

Gen que da origen a una proteína que repara el ADN dañado. Las mutaciones (cambios) en el gen BRCA1 aumentan mucho el riesgo de presentar cáncer de mama y cáncer de ovario.

Feb 14, 2025 · A team of researchers led by Shyam K. Sharan, Ph.D., Senior Investigator in the Mouse Cancer Genetics Program, has categorized over 6,500 possible single nucleotide variants (SNVs) in the BRCA2 protein as either benign or potentially cancerous.The study was published in Nature on February 13, 2025.. BRCA2 is a protein that is involved in repairing DNA and …

Jan 29, 2018 · The Food and Drug Administration has approved olaparib (Lynparza®) to treat metastatic breast cancers that have inherited mutations in the BRCA1 or BRCA2 genes as well as a companion diagnostic test for selecting candidates for the therapy.

Jun 26, 2019 · Olaparib (Lynparza) may benefit some people with advanced pancreatic cancer who have BRCA1 or BRCA2 mutations, according to the POLO trial results.

Long before scientists completed mapping the human genome in 2003, geneticist Mary-Claire King discovered BRCA1, the first gene for a hereditary form of breast cancer. That feat in 1990 helped explain why some women who carried mutations in this gene saw their lifetime risk for developing breast cancer rise from 8% to over 80%.